Skip to main content
Moleculin gets fast-track status for AML drug
4/19/2019

Moleculin Biotech's Annamycin, which is being developed as a treatment for patients with relapsed or refractory acute myeloid leukemia and is in early-stage and midstage trials, has been granted fast-track designation by the FDA.

Full Story: